Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2022

View Archived Issues

ProfoundBio presents novel ADCs for cancer treatment

University of California discloses new PRMT8 inhibitors

Vertex Pharmaceuticals patents CFTR potentiators

Dana-Farber Cancer Institute discloses new HER2 inhibitors

Merck & Co. presents DGAT-2 inhibitors

Idorsia Pharmaceuticals patents LGALS3 inhibitors

AC-0027875, a gamma-secretase modulator for the treatment of AD

To escape radiation, tumor cells reversibly damage their DNA

Discovery of pyrrolo-pyridine benzamide derivative with promising antitumor efficacy in vivo

Apramycin shows efficacy in models of Mycobacterium abscessus infections

Discovery of novel D4R antagonist with favorable in vivo PK profile

ProMIS reports potential therapeutic approaches for ALS and nominates lead candidate

Series A financing supports Kelonia's development of in vivo gene delivery technology

HanAll advances novel immuno-oncology antibodies HL-187/HL-186

Chimera Bioengineering advances preclinical testing of CAR-T therapy CBIO-007 for solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...